Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

SANOFI SYNTHELABO

Home Clinical Trial Sponsors and OrganizationsSANOFI SYNTHELABO

SANOFI SYNTHELABO

NASR CITY, 11 Mohamed Mandour St., Rabaa El Adaweya, Cairo, Egypt

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

13

12 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Not Applicable

1

7.7%

Trial Status Distribution

Active, not recruiting

12

92.3%

Unknown

1

7.7%

Clinical Trials

Trials sponsored by this organization (13)

Comparative Efficacy, Safety And Tolerability Of Three Treatment Regiments For Uncomplicated Falciparum Malaria

Jan 2018750 participants

randomized, double blind, two-arm placebo controlled, 12-Month study of the effects of rimonabant 20 mg once daily on amount and activity of visceral fat in abdominally obese patients with metabolic syndrome. - Visceral fat reduction assessed by CT-scan On RImonabAnt

Active, not recruiting

Jan 2007232 participants

A randomized, double blind, two-arms placebo-controlled, parallel group, multicenter study of rimonabant 20 mg once daily in the treatment of atherogenic dyslipidemia in abdominally obese patients

Active, not recruiting

Mar 2006740 participants

Double-blind placebo COntrolled dose Ranging studYof the eFficacy and safEty of SSR149744C 300 or 600 mg for the conversion of atrial fibrillation/fluttEr CORYFEE

Active, not recruiting

Mar 2006141 participants

olpitantium Besylate in patients with mild to moderate Ulcerative Colitis a double-blind, placebo controlled efficacy and safety, 8-week study

Active, not recruiting

Feb 2006300 participants

A multicenter randomized, double-blind placebo controlled phase III study of the efficacy of Xaliproden in preventing the neurotoxicity of oxaliplatin in first-line treatment of patients with metastatic colorectal cancer treated with oxaliplatin/5FU/LV

Active, not recruiting

Jan 2006900 participants

A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patients with Atrial fibrillation/atrial flutter (AF/AFL)

Active, not recruiting

Nov 20053,700 participants

SOLIAN solution in the acute setting

Active, not recruiting

Jul 2005500 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials13
Approvals
News

Back to Organizations